The US Food and Drug Administration (FDA) has granted breakthrough device designation for Acrivon Therapeutics’ ACR-368 ...

Acrivon Therapeutics, Inc.’s ACRV share price has surged by 17.94%, which has investors questioning if this is right time to ...

The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, ...

We recently published a list of 12 AI News and Ratings Investors are Keeping Their Eye On. In this article, we are going to ...

The ACR-368-tailored OncoSignature assay is being used to identify patients most likely to respond to the company's lead drug candidate ACR-368 in an ongoing, registrational-intent, phase IIb trial in ...

Acrivon Therapeutics said the Food and Drug Administration has granted Breakthrough Device designation for its ACR-368 OncoSignature assay, an immunofluorescence assay for the identification of ...

China Universal Asset Management Co. Ltd. bought a new stake in Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Free Report) during the fourth quarter, according to the company in its most recent 13F filing ...

Fintel reports that on January 31, 2025, Cantor Fitzgerald initiated coverage of Acrivon Therapeutics (NasdaqGM:ACRV) with a Overweight recommendation. Analyst Price Forecast Suggests 260.44% Upside ...

On Friday, Cantor Fitzgerald analysts initiated coverage of Acrivon Therapeutics Inc (NASDAQ:ACRV) with an Overweight rating. The initiation comes with a positive outlook on the company's potential in ...

Acrivon Therapeutics, Inc. (NASDAQ: ACRV), a clinical stage biopharmaceutical company with a market capitalization of $184 million and an impressive 60% stock return over the past year, announced that ...